Edition:
United States

Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

1.26USD
17 Aug 2017
Change (% chg)

$-0.02 (-1.56%)
Prev Close
$1.28
Open
$1.30
Day's High
$1.30
Day's Low
$1.26
Volume
6,014
Avg. Vol
5,231
52-wk High
$3.09
52-wk Low
$1.11

ACST.OQ

Chart for ACST.OQ

About

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia... (more)

Overall

No Ratios Available.

Financials

  ACST.OQ Industry Sector
P/E (TTM): -- 31.64 32.84
EPS (TTM): -- -- --
ROI: -- 15.30 14.86
ROE: -- 16.32 16.11

BRIEF-Acasti Pharma reports Q1 loss per share c$0.19

* Acasti Pharma reports first quarter fy 2018 financial results

Aug 14 2017

BRIEF-Acasti Pharma issues common shares in payment of outstanding interest under debentures

* Acasti Pharma announces issuance of common shares in payment of outstanding interest under debentures Source text for Eikon: Further company coverage:

Jul 28 2017

BRIEF-Acasti Pharma reports Q4 and FY 2017 financial results

* Acasti Pharma reports fourth quarter and full-year 2017 financial results

Jun 06 2017

BRIEF-Acasti Pharma, CordenPharma announce large scale production of CaPre with new continuous manufacturing process

* Acasti Pharma and CordenPharma announce large scale production of Capre with new continuous manufacturing process Source text for Eikon: Further company coverage:

May 31 2017

BRIEF-Acasti Pharma says has successfully completed two Phase 1, two Phase 2 clinical trials with Capre

* Acasti Pharma Inc - has successfully completed two Phase 1 and two Phase 2 clinical trials with Capre for treatment of hypertriglyceridemia

Apr 12 2017

BRIEF-Acasti Pharma provides update on Capre phase 3 development program

* Acasti Pharma provides update on Capre phase 3 development program

Mar 30 2017

Earnings vs. Estimates